Risk and incidence of cardiovascular disease associated with polycystic ovary syndrome

Aims We aimed to evaluate the risk of cardiovascular disease (CVD) in women with polycystic ovary syndrome (PCOS) and estimate the global incidence of PCOS-associated CVD.Methods and results We conducted a meta-analysis across five databases to evaluate the risk of CVD among women with PCOS. The global incidence of PCOS-associated CVD was calculated by a population attributable fraction modelling using the pooled risk ratio (RR), PCOS prevalence, CVD incidence number, and age-standardized rate (ASIR), from the Global Burden of Diseases 2019. An estimated annual percentage change (EAPC) was used to assess the temporal trend of PCOS-associated CVD. The risk of CVD was significantly increased in women with PCOS for an all-age group (pooled RR 1.51, 95% confidence interval 1.36-1.69) and 10- to 54-year-olds (1.37, 1.17-1.59). Globally, from 1990 to 2019, the PCOS-associated CVD cases in women across the all-age group has raised from 102 530 to 235 560. The most affected regions were East Asia and the Pacific (108 430, 66 090-166 150) in 2019. South Asia has the highest increase trend of PCOS-associated CVD ASIRs (EAPC 2.61%, 2.49-2.73). The annual increase in ASIR in PCOS-CVD incidence for the 10-54 age group (EAPC 0.49%, 0.41-0.56) is faster than that of the all-age group (0.34, 0.27-0.42). The middle- or low-middle sociodemographic index countries experienced higher increase trend of CVD due to PCOS in the past 30 years.Conclusion Women with PCOS have a significantly increased risk of CVD. Efficient measures to enhance its prevention and treatment are important for regions with a high PCOS-associated CVD burden, especially premature CVD in women under 55 years. Studies have reported that cardiovascular disease (CVD) is the leading cause of mortality for women. Meanwhile, women with polycystic ovary syndrome (PCOS) substantially elevate the risk of CVD. However, no studies have quantified the impact of PCOS on the overall CVD burden. This study performed a meta-analysis to assess the risk of CVD in an all-age group and 10- to 54-year-old women, living with PCOS with 17 articles, and estimated the burdens of PCOS-associated CVD burden globally, in 7 World Bank-defined regions, and in 204 countries, from 1990 to 2019, using population attributable fraction (PAF) modelling. Our study implicated that women in all-age group and 10 to 54 years old with PCOS face a 1.51-fold and 1.37-fold increased risk of CVD compared to those without, respectively. Globally, similar to 0.85% of CVD new cases in 2019 were associated with PCOS, corresponding to a more than two-fold increase in PCOS-associated CVD cases from 1990. However, the burden of PCOS-associated CVD varies widely by region; for instance, nearly 1.49% of CVD new cases were attributed to PCOS in North America. Meanwhile, the East Asia and Pacific region had the highest PCOS-associated new CVD case, and South Asia experienced the highest increase in age-standardized incidence rates of CVD due to PCOS. Notably, we found higher worldwide PAFs and an annual increase in ASIR than that in all-age group women. This result suggests that premature CVDs in women with PCOS under 55 years deserve more attention.